Literature DB >> 832019

Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.

J A Kanis, R G Russell.   

Abstract

The rate of reversal of hypercalcaemia or hypercalciuria induced by calciferol, dihydrotachysterol, 1-alpha-hydroxycholecalciferol (1-alpha-OHD3), or 1-alpha, 25-dihydroxycholecalciferol (1-alpha, 25-(OH)2D3) was measured in three normal subjects, two patients with osteoporosis, and 14 patients with disorders resistant to vitamin D. The half time for reversal after stopping 1-alpha, 25 (OH)2D3 was less than that after stopping 1-alpha-OHD3, calciferol, or dihydrotachysterol. The differences observed were independent of the dose given or length of treatment. When 1-alpha-OHD3 or 1-alpha-25-(OH)2D3 was stopped patients with vitamin D resistant states (hypoparathyroidism, renal tubular hypophosphataemia, or chronic renal failure) showed less rapid reversal of hypercalcaemia and hypercalciuria than did normal subjects. These studies show one potential advantage of 1-alpha-25-(OH)2D3 over vitamin D, and possibly over 1-alpha-OHD3, in the management of vitamin D resistant states.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 832019      PMCID： PMC1604081          DOI： 10.1136/bmj.1.6053.78

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  4 in total

1.  1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism.

Authors:  R G Russell; R Smith; R J Walton; C Preston; R Basson; R G Henderson; A W Norman
Journal:  Lancet       Date:  1974-07-06       Impact factor: 79.321

2.  Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.

Authors:  R G Henderson; R G Russell; J G Ledingham; R Smith; D O Oliver; R J Walton; D G Small; C Preston; G T Warner
Journal:  Lancet       Date:  1974-03-09       Impact factor: 79.321

3.  Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.

Authors:  S W Kooh; D Fraser; H F DeLuca; M F Holick; R E Belsey; M B Clark; T M Murray
Journal:  N Engl J Med       Date:  1975-10-23       Impact factor: 91.245

4.  Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.

Authors:  A M Pierides; H A Ellis; W Simpson; J H Dewar; M K Ward; D N Kerr
Journal:  Lancet       Date:  1976-05-22       Impact factor: 79.321
  4 in total
  25 in total

1.  Reversible vascular calcifications associated with hypervitaminosis D.

Authors:  Massimo Cirillo; Giancarlo Bilancio; Chiara Cirillo
Journal:  J Nephrol       Date:  2015-08-30       Impact factor: 3.902

2.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

3.  Clinical use of 1-alpha-hydroxyvitamin D3.

Authors: 
Journal:  Br Med J       Date:  1978-06-17

4.  Treatment of osteoporosis with vitamin D.

Authors:  J A Kanis; E V McCloskey; D de Takats; J Bernard; D M Zhang
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 5.  Vitamin D and analogues in renal bone disease and implications for osteoporosis.

Authors:  J A Kanis; E V McCloskey; M N Beneton
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 6.  The pathophysiology and clinical aspects of hypercalcemic disorders.

Authors:  D B Lee; E T Zawada; C R Kleeman
Journal:  West J Med       Date:  1978-10

7.  Studies on the mode of action of vitamin D XXXVII 1 alpha-hydroxyvitamin D3: a long-acting 1,25-dihydroxyvitamin D3 analog.

Authors:  M R Walters; W Hunziker; J E Bishop; A W Norman
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

8.  1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells.

Authors:  Y Honma; M Hozumi; E Abe; K Konno; M Fukushima; S Hata; Y Nishii; H F DeLuca; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

9.  Renal handling of calcium in hypoparathyroidism.

Authors:  G H Newman; M Wade; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

10.  Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man?

Authors:  J A Kanis; T Cundy; M Bartlett; R Smith; G Heynen; G T Warner; R G Russell
Journal:  Br Med J       Date:  1978-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.